OVARIAN CANCER and US: patients opinion

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Showing posts with label patients opinion. Show all posts
Showing posts with label patients opinion. Show all posts

Monday, May 23, 2011

Patient's Opinion: Molecular Profiling



Both Jean Mckibben and Debbie Bozsa post on ACOR (Mailing List - Ovarian Cancer) about molecular profiling at The Clearity Foundation and their website:www.clearityfoundation.org multiple times this year.
----------------------------------------------------------------------------------------------------------
"I had my 4th debulking surgery on 3/3/11 for my 5th recurrence. Initially, I did not think about to do molecular profiling because I thought it will need a lot paper work, energy and money to do it.  When you go through lot of treatments for ovarian cancer, you feel that every minute counts down your life, and you just want to spend time and money for something enjoyable. Jean encouraged me to do the molecular profiling when we exchanged email privately.  I sent in my request for the test on 3/16/11, and I got my partial result in a month, and the final result on 5/16/11. I highly recommend the test. After my surgery, my chemotherapy choice was Doxil or Topotecan.  I tried Doxil first, and then molecular profiling showed I am benefit from Doxil, not benefit from Topotecan. Now my doctor treats me with the confidence based on those biomarkers. My CA125 has been going down with 2 treatments although I have skin rash and lesions due to the side effects of Doxil.

When you go to Clearity Foundation web site, there are 3 parts.

1. Caris Life Science: They do Target Now biomarkers for drugs including: paclitaxel/docetaxel, cisplatin/carboplatin, trastuzumab, letrozole, tamoxifen, doxorubicin, topotecan/irinotecan and temozolomide. They will tell you from which drug you may benefit, which not, based on your biomarkers. There is an 11 page report sent to your doctor, including biomarker description and reference. They send the bill to insurances and patients. 

2. Clarient, Inc:  They do more tests for biomarkers to compare your biomarkers to other ovarian cancer patients in their Diane Barton Database. Dr. Laura Shawver, the founder of The Clearity Foundation, will email the result to you and call you to explain the result, and may suggest some new target therapy or clinical trials. The Clarient test will be paid by Clearity Foundation. 

3. The Clearity Foundation: They help people to pay the test cost if patients have no insurance or their insurances do not pay for the test.  They have a one page grant application for patients to complete, and can approve the application by email in one day.  People working at The Clearity Foundation are very friendly and helpful. Please call 1-855-856-0654 if you have any question.  

Please know that molecular profiling is different from tumor sensitivity or resistant assay.  Tumor sensitivity or resistant assay uses fresh tissue to culture tumor cells, add different chemo drugs, and then sees which chemo drug  kills them (cancer cells).  When I had my 3th debulking surgery for my 4th recurrence one year ago, my doctor sent for a tumor resistant assay. However, I did not get any result from the test because my tumor cells did not grow in their cell culture. The molecular profiling test uses tumor samples from biopsy or surgery in paraffin sections. The samples do not need to be fresh, can be a few years old. They do special staining to find biomarkers."

Yi